Evaluating 10-kHz Spinal Cord Stimulation to Reduce Pain and Improve Quality of Life in Adults with Chemotherapy-Induced Peripheral Neuropathy

What this Trial Is About

Researchers are evaluating how spinal cord stimulation SCS affects pain levels and quality of life in adults with chemotherapy-induced peripheral neuropathy CIPN. CIPN is a nerve condition caused by chemotherapy that leads to pain, numbness, tingling, swelling, or muscle weakness, usually starting in the hands or feet and worsening over time. SCS is a therapy used for several non-cancer pain disorders and is being studied here for its potential benefits in CIPN. Participants receive spinal cord stimulation therapy and complete questionnaires about their pain and quality of life at the start of the study and again at 3, 6, and 12 months. The study measures include the percentage of participants with at least 50% reduction in lower extremity pain at 6 months, neurological improvements, overall satisfaction, health-related quality of life, sleep disturbances, and any adverse events related to SCS therapy. During the study, participants fill out questionnaires that take about 30 minutes each at multiple time points to assess pain intensity and neurological status. Researchers also monitor sleep issues and adverse effects throughout. The total study duration for each participant is 12 months, with assessments at baseline, 3, 6, and 12 months to understand how SCS impacts pain and quality of life over time.

Assessing Effect of Spinal Cord Stimulation on Pain and Quality of Life With Chemotherapy-Induced Peripheral Neuropathy